Overview

NGS 20-gene lung cancer testing uses high-throughput sequencing to survey twenty cancer-related genes in a single assay, helping identify alterations that guide targeted therapy. Behind the report is a multi-step workflow that turns a small tumor sample into an interpretable variant list. This article walks through the molecular mechanism of that workflow without overstating clinical outcomes, so procurement and lab teams understand what the result actually depends on. Appreciating each step helps non-specialists interpret the report responsibly, because the final variant list is only as trustworthy as the extraction, library, and alignment stages that precede it; weak input at any single point propagates into uncertain output that can mislead therapy and delay appropriate care.

From Sample to Sequencing-Ready Library

Tumor DNA or RNA is extracted from the received specimen and assessed for quality. Fragments are attached to platform-specific adapters, and amplification builds a sequencing-ready library. For lung cancer, the panel is enriched for genes such as EGFR, ALK, ROS1, BRAF, and KRAS, so the library preparation concentrates reads on regions most likely to carry actionable changes while limiting wasted coverage on irrelevant sequence.

Sequencing by Synthesis and Read Alignment

Modern platforms read millions of short fragments through sequencing by synthesis, recording the order of nucleotides as fluorescent signals. Bioinformatics then aligns these reads to a reference genome, comparing the tumor sequence against normal to distinguish true alterations from background noise. Coverage depth determines how confidently rare variants are called, and duplicate marking helps remove amplification artifacts before interpretation.

Variant Calling and Interpretation

After alignment, the pipeline identifies substitutions, small insertions or deletions, and copy-number or fusion events. Each finding is classified by known significance, and alterations of unknown significance are separated from those with therapy or trial associations. The final report translates the molecular readout into a concise list the care team can act on, with clear notation of confidence for each called variant.

FAQ

Q: What does the 20-gene panel actually measure? A: It sequences twenty selected cancer-related genes to find substitutions, indels, copy changes, and fusions relevant to lung cancer care.

Q: Why is coverage depth important? A: Higher depth improves confidence in detecting low-frequency variants and reduces false calls from sequencing noise.

Q: Are all detected variants clinically actionable? A: No. Many are variants of unknown significance; only those with established therapy or trial links should drive decisions.